Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.32 |
| ▸ | KDM5A | P29375 | 4/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23807269 | 0.91 | GGPS1 (0.53) | GGPS1DNM1TSHRKDM4CKDM5A | |
| SCHEMBL21689253 | 0.89 | ALDH1A1 (0.50) | GGPS1ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL13440507 | 0.84 | GGPS1 (0.32) | GGPS1 | |
| SCHEMBL14580744 | 0.81 | ALDH1A1 (0.52) | GGPS1ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL15563344 | 0.81 | GGPS1 (0.49) | GGPS1ALDH1A1TDP1DNM1CYP3A4 | |
| SCHEMBL28084013 | 0.81 | GGPS1 (0.49) | GGPS1ALDH1A1TDP1DNM1CYP3A4 | |
| SCHEMBL20298545 | 0.79 | ALDH1A1 (0.50) | GGPS1ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL14060216 | 0.79 | LMNA (0.52) | GGPS1ALDH1A1DNM1TSHRKDM4C | |
| SCHEMBL21387556 | 0.79 | DNM1 (0.46) | GGPS1ALDH1A1TDP1DNM1CYP3A4 | |
| SCHEMBL19936946 | 0.78 | GGPS1 (0.41) | GGPS1DNM1KDM4CKDM5AS1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | GGPS1 1707/4885ALDH1A1 343/4885TDP1 649/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | GGPS1 1394/4885ALDH1A1 265/4885TDP1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.